Design and validation by integrative InmunoProteoGenomics strategy of biomarkers for accelerating the knowledge in B-cell chronic lymphocytic leukemia as model and other malignant hemopaties

The main goal of the current projects is to design and develop a multiparametric strategy, inmunoproteogenomics, with easy translation into the clinic, for the validation of tumor associated proteins of Chronic lymphocytic leukemia (B-CLL) and directly related with the treatment protocol. This validation will be performed by the systematic and comprehensive integration of genomics, transcriptomics, proteomics and next-generation of immunoassays.
The list of aims is: 1. Connection somatic mutation and to cell signaling pathways. 2. Profiling quantitative proteome and PTMs patterns between aberrant B cells and healthy ones. 3. Orthogonal validation by next-generation immunoassays in array format.
Methodology: 1. Mutational profiling by single cell platform. 2. Quantitative proteomics characterization of global proteome and PTMs patterns. 3. Ortogonal validation by immunoproteogenomics strategy. Finally, all the data will be integrated and correlated with the clinical-biological data.